FDA OKs hot-flash drug from Pfizer, Ligand

10/4/2013 | Bloomberg

The FDA has granted Pfizer and Ligand Pharmaceuticals approval for their osteoporosis and hot-flash treatment Duavee. The medication is to be used in postmenopausal women who haven't had a hysterectomy and who suffer moderate to severe hot flashes. The drug is also indicated for prevention of post-menopausal osteoporosis.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA